Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

Rhea-AI Summary

Mustang Bio, Inc. (MBIO) announced that Manuel Litchman, M.D., President and CEO, will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference on January 18, 2024, at 4:30 p.m. EST, focusing on the translation of medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases.

WORCESTER, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference, taking place on Thursday, January 18, 2024, at 4:30 p.m. EST.

To access this event, please RSVP to your B. Riley Securities sales representative. A replay of Mustang’s fireside chat will be available on this link after the meeting.

About Mustang Bio
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR-T therapies across multiple cancers, as well as lentiviral gene therapies for severe combined immunodeficiency. Mustang’s common stock is registered under the Securities Exchange Act of 1934, as amended, and Mustang files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). Mustang was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.mustangbio.com.

Company Contacts:
Jaclyn Jaffe and Nicole McCloskey
Mustang Bio, Inc.
(781) 652-4500
ir@mustangbio.com

FAQ

When is the B. Riley Securities 4th Annual Oncology Conference taking place?

The conference is scheduled to take place on Thursday, January 18, 2024.

Who will be participating in the fireside chat at the conference?

Manuel Litchman, M.D., President and CEO of Mustang Bio, Inc., will be participating in the fireside chat.

What is the focus of Mustang Bio, Inc.?

Mustang Bio, Inc. is focused on translating medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases.

How can one access the event?

To access the event, one needs to RSVP to their B. Riley Securities sales representative. A replay of the fireside chat will be available on a provided link after the meeting.